Novel therapies for children with acute myeloid leukaemia.
about
High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcomeMolecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.Targeting cell cycle regulators in hematologic malignancies.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model.Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo.Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cellsMolecular therapeutic approaches for pediatric acute myeloid leukemia.The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry.Socioeconomic disparities in survival from childhood leukemia in the United States and globally: a meta-analysis.Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesylation of Ras.miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells.Protective effect of breastfeeding against childhood leukemia in Zhejiang Province, P. R. China: a retrospective case-control study
P2860
Q33667247-4718BEC3-12EB-4B93-A4F0-E702C94F98DAQ35016583-9DF57982-9CE8-4910-8FF0-E273BF61B2DDQ35334436-8492A050-CC48-4166-B19D-C80390B17059Q35687836-A6ACCB17-2508-4E76-B2B3-2237DD4B976EQ36038920-07994159-25AF-4D20-90E7-8D9217E6B6EDQ36053792-48E9EE59-D282-4917-AEFE-842F1C99FB7EQ36413478-92396D2C-E006-4A7E-9762-F4ED053C6D1AQ37118668-B39D8451-F24C-48F9-A2A8-AA1368724FD1Q37636705-3DFE21CF-4475-4EE4-89BB-43A825C8D67CQ37643136-A90E1B7C-98C3-4E5E-AB54-40F7691CE05BQ41099096-E784474E-08F8-43FC-9ECE-94BEBC3FFA61Q41665595-93A2B119-1666-4C04-B091-254612E17E4BQ47136441-09CC82AB-B792-4FAC-BE24-3E65BA3753C3Q50159472-FE2A6E17-0C87-4C96-8812-D18C86B470EBQ52714610-1D008BCC-574C-4185-A7AC-05587B52E933Q54988438-F7B9748E-91A3-42F8-B8B6-3CD31CCA0374Q58712253-3E2B3628-CAB9-47CB-8E8A-A09D7CC1A677
P2860
Novel therapies for children with acute myeloid leukaemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Novel therapies for children with acute myeloid leukaemia.
@en
type
label
Novel therapies for children with acute myeloid leukaemia.
@en
prefLabel
Novel therapies for children with acute myeloid leukaemia.
@en
P2093
P2860
P356
P1433
P1476
Novel therapies for children with acute myeloid leukaemia
@en
P2093
A D J Pearson
P R Kearns
P2860
P2888
P304
P356
10.1038/LEU.2013.106
P577
2013-04-08T00:00:00Z
P6179
1046913171